These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24277740)

  • 1. Antipneumococcal seroprevalence and pneumococcal carriage during a meningococcal epidemic in Burkina Faso, 2006.
    Yaro S; Njanpop-Lafourcade BM; Drabo A; Idohou RS; Kroman SS; Sanou O; Traoré Y; Sangaré L; Diagbouga SP; Koeck JL; Borrow R; Gessner BD; Mueller JE
    J Infect Dis; 2014 Apr; 209(8):1241-50. PubMed ID: 24277740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo.
    Traore Y; Tameklo TA; Njanpop-Lafourcade BM; Lourd M; Yaro S; Niamba D; Drabo A; Mueller JE; Koeck JL; Gessner BD
    Clin Infect Dis; 2009 Mar; 48 Suppl 2():S181-9. PubMed ID: 19191614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002.
    Raghunathan PL; Jones JD; Tiendrebéogo SR; Sanou I; Sangaré L; Kouanda S; Dabal M; Lingani C; Elie CM; Johnson S; Ari M; Martinez J; Chatt J; Sidibe K; Schmink S; Mayer LW; Kondé MK; Djingarey MH; Popovic T; Plikaytis BD; Carlone GM; Rosenstein N; Soriano-Gabarró M
    J Infect Dis; 2006 Mar; 193(5):607-16. PubMed ID: 16453255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal carriage and immunity in western Burkina Faso, 2003.
    Yaro S; Traoré Y; Tarnagda Z; Sangaré L; NjanpopLafourcade BM; Drabo A; Findlow H; Borrow R; Nicolas P; Gessner BD; Mueller JE
    Vaccine; 2007 Sep; 25 Suppl 1():A42-6. PubMed ID: 17559988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing.
    Parent du Châtelet I; Traore Y; Gessner BD; Antignac A; Naccro B; Njanpop-Lafourcade BM; Ouedraogo MS; Tiendrebeogo SR; Varon E; Taha MK
    Clin Infect Dis; 2005 Jan; 40(1):17-25. PubMed ID: 15614687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso.
    Yaro S; Lourd M; Traoré Y; Njanpop-Lafourcade BM; Sawadogo A; Sangare L; Hien A; Ouedraogo MS; Sanou O; Parent du Châtelet I; Koeck JL; Gessner BD
    Clin Infect Dis; 2006 Sep; 43(6):693-700. PubMed ID: 16912941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.
    Blumental S; Moïsi JC; Roalfe L; Zancolli M; Johnson M; Burbidge P; Borrow R; Yaro S; Mueller JE; Gessner BD; Goldblatt D
    Clin Vaccine Immunol; 2015 Apr; 22(4):404-12. PubMed ID: 25651921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine-Burkina Faso, 2011-2013.
    Kambiré D; Soeters HM; Ouédraogo-Traoré R; Medah I; Sangare L; Yaméogo I; Sawadogo G; Ouédraogo AS; Hema-Ouangraoua S; McGee L; Srinivasan V; Aké F; Congo-Ouédraogo M; Sanou S; Ba AK; Novak RT; Van Beneden C;
    PLoS One; 2016; 11(11):e0166384. PubMed ID: 27832151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity.
    Mueller JE; Yaro S; Njanpop-Lafourcade BM; Drabo A; Idohou RS; Kroman SS; Sanou O; Diagbouga S; Traoré Y; Sangaré L; Borrow R; Gessner BD
    J Infect Dis; 2011 Dec; 204(11):1787-95. PubMed ID: 21998478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017.
    Soeters HM; Kambiré D; Sawadogo G; Ouédraogo-Traoré R; Bicaba B; Medah I; Sangaré L; Ouédraogo AS; Ouangraoua S; Yaméogo I; Congo-Ouédraogo M; Ky Ba A; Aké F; Srinivasan V; Novak RT; McGee L; Whitney CG; Van Beneden C
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S253-S262. PubMed ID: 31671444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal serotype distribution among meningitis cases from Togo and Burkina Faso during 2007-2009.
    Gessner BD; Sanou O; Drabo A; Tamekloe TA; Yaro S; Tall H; Moïsi JC; Mueller JE; Njanpop-LaFourcade BM
    Vaccine; 2012 Dec; 30 Suppl 6():G41-5. PubMed ID: 23228357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.
    Trotter CL; Yaro S; Njanpop-Lafourcade BM; Drabo A; Kroman SS; Idohou RS; Sanou O; Bowen L; Findlow H; Diagbouga S; Gessner BD; Borrow R; Mueller JE
    PLoS One; 2013; 8(2):e55486. PubMed ID: 23457471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003.
    Mueller JE; Yaro S; Traore Y; Sangare L; Tarnagda Z; Njanpop-Lafourcade BM; Borrow R; Gessner BD
    J Infect Dis; 2006 Mar; 193(6):812-20. PubMed ID: 16479516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis-Burkina Faso, 2014-2015.
    Kambiré D; Soeters HM; Ouédraogo-Traoré R; Medah I; Sangaré L; Yaméogo I; Sawadogo G; Ouédraogo AS; Ouangraoua S; McGee L; Srinivasan V; Aké F; Congo-Ouédraogo M; Ky Ba A; Whitney CG; Novak RT; Van Beneden C;
    J Infect; 2018 Mar; 76(3):270-279. PubMed ID: 29253559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of respiratory tract infection symptoms and air humidity with meningococcal carriage in Burkina Faso.
    Mueller JE; Yaro S; Madec Y; Somda PK; Idohou RS; Lafourcade BM; Drabo A; Tarnagda Z; Sangaré L; Traoré Y; Fontanet A; Gessner BD
    Trop Med Int Health; 2008 Dec; 13(12):1543-52. PubMed ID: 18983283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults.
    Gessner BD; Mueller JE; Yaro S
    BMC Infect Dis; 2010 Feb; 10():22. PubMed ID: 20146815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of the immunization coverage determinants of vaccination campaign against meningococcal A meningitis in Burkina Faso].
    Ouatara S; Faye A; Leye MM; Niang K; Tal-Dia A
    Rev Epidemiol Sante Publique; 2015 Dec; 63(6):347-53. PubMed ID: 26547670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.